GlassScriptPhysician profile
Megan Mckee
NPI 1114161411
$5,683.98
in general payments reported to CMS, 2019-2025
49 companies · $1,870 in 2025
The $1,870 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $314 · 2021: $197 · 2022: $637 · 2023: $1,168 · 2024: $1,213 · 2025: $1,870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,236 · Education: $16.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,235.66 |
| Education | $16.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $413.37 | 2019-2025 | Keytruda, Welireg |
| Pfizer INC. | $392.75 | 2019-2025 | |
| Seagen INC. | $303.43 | 2019-2023 | Adcetris, Padcev, Tivdak |
| Genzyme Corporation | $301.65 | 2021-2025 | |
| Abbvie INC. | $270.77 | 2022-2025 | |
| Glaxosmithkline, LLC. | $258.87 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Janssen Biotech, INC. | $258.63 | 2019-2025 | Darzalex, Erleada, Talvey |
| Beigene USA, INC. | $249.93 | 2023-2025 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $240.45 | 2019-2025 | |
| Astellas Pharma US INC | $236.22 | 2020-2025 | Padcev, Vyloy, Xtandi |
| Array Biopharma INC | $199.15 | 2022-2025 | Braftovi, Lorbrena, Mektovi |
| Lilly USA, LLC | $187.81 | 2020-2025 | Verzenio, Jaypirca |
| Astrazeneca Pharmaceuticals LP | $182.37 | 2019-2025 | Enhertu, Lynparza, Tagrisso |
| Genentech USA, INC. | $176.83 | 2019-2025 | Phesgo, Polivy, Itovebi |
| Puma Biotechnology, INC. | $159.33 | 2022-2025 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Mckee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.